66 Nao
1 known investors
脑动极光 (66nao) develops medical-grade digital therapeutics that combine brain science with AI to assess and treat cognitive impairment caused by vascular disease, neurodegenerative disease, psychiatric disorders, and childhood developmental deficits. It operates in China's cognitive disorder digital therapeutics market and states its core product was the first regulator-approved cognitive disorder digital therapeutic in China.
Founders & leadership
蔡
蔡龙军首席技术官兼首席运营官、代理首席执行官兼代理首席研发官 (CTO & COO, Acting CEO & Acting CRDO)
王
王俊杰首席财务官及联席公司秘书 (CFO & Joint Company Secretary)
赖
赖知远市场及运营副总裁 (VP of Marketing and Operations)
谭
谭铮董事会主席、执行董事兼首席战略官 (Chairman & Chief Strategy Officer)
Investors · 1
Frequently asked questions
- What does 66 Nao do?
- 脑动极光 (66nao) develops medical-grade digital therapeutics that combine brain science with AI to assess and treat cognitive impairment caused by vascular disease, neurodegenerative disease, psychiatric disorders, and childhood developmental deficits. It operates in China's cognitive disorder digital therapeutics market and states its core product was the first regulator-approved cognitive disorder digital therapeutic in China.
- Who are 66 Nao's investors?
- 66 Nao's investors include F-Prime Capital.